Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Myocardial Fibrosis - Overview
Myocardial Fibrosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myocardial Fibrosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myocardial Fibrosis - Companies Involved in Therapeutics Development
Evotec SE
Galectin Therapeutics Inc
Guangdong Maijinjia Biotechnologies Co Ltd
Invivosciences Inc
Lead Discovery Center GmbH
MandalMed Inc
NovoMedix LLC
Palatin Technologies Inc
Pharmaxis Ltd
Puretech Health Plc
TRACON Pharmaceuticals Inc
Vectus Biosystems Ltd
Myocardial Fibrosis - Drug Profiles
belapectin - Drug Profile
Product Description
Mechanism Of Action
deupirfenidone - Drug Profile
Product Description
Mechanism Of Action
Drugs for Tissue Fibrosis - Drug Profile
Product Description
Mechanism Of Action
Fibrosis in Heart Muscle - Drug Profile
Product Description
Mechanism Of Action
GMCT-01 - Drug Profile
Product Description
Mechanism Of Action
GYY-4137 - Drug Profile
Product Description
Mechanism Of Action
IVS-201 - Drug Profile
Product Description
Mechanism Of Action
IVS-202 - Drug Profile
Product Description
Mechanism Of Action
Monoclol Antibodies to Inhibit Marinobufagenin for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
NM-922 - Drug Profile
Product Description
Mechanism Of Action
PL-5028 - Drug Profile
Product Description
Mechanism Of Action
PN1-Ab - Drug Profile
Product Description
Mechanism Of Action
PXS-5153A - Drug Profile
Product Description
Mechanism Of Action
PXS-5382A - Drug Profile
Product Description
Mechanism Of Action
Recombint Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile
Product Description
Mechanism Of Action
RHO GEF - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile
Product Description
Mechanism Of Action
TPI-2049 - Drug Profile
Product Description
Mechanism Of Action
TRC-205 - Drug Profile
Product Description
Mechanism Of Action
VB-0004 - Drug Profile
Product Description
Mechanism Of Action
Myocardial Fibrosis - Dormant Projects
Myocardial Fibrosis - Discontinued Products
Myocardial Fibrosis - Product Development Milestones
Featured News & Press Releases
Oct 08, 2019: Publication that demonstrates reversal of established fibrosis in a preclinical model of cardiac fibrosis by VIP
Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Myocardial Fibrosis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Myocardial Fibrosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Myocardial Fibrosis - Pipeline by Evotec SE, 2022
Myocardial Fibrosis - Pipeline by Galectin Therapeutics Inc, 2022
Myocardial Fibrosis - Pipeline by Guangdong Maijinjia Biotechnologies Co Ltd, 2022
Myocardial Fibrosis - Pipeline by Invivosciences Inc, 2022
Myocardial Fibrosis - Pipeline by Lead Discovery Center GmbH, 2022
Myocardial Fibrosis - Pipeline by MandalMed Inc, 2022
Myocardial Fibrosis - Pipeline by NovoMedix LLC, 2022
Myocardial Fibrosis - Pipeline by Palatin Technologies Inc, 2022
Myocardial Fibrosis - Pipeline by Pharmaxis Ltd, 2022
Myocardial Fibrosis - Pipeline by Puretech Health Plc, 2022
Myocardial Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, 2022
Myocardial Fibrosis - Pipeline by Vectus Biosystems Ltd, 2022
Myocardial Fibrosis - Dormant Projects, 2022
Myocardial Fibrosis - Dormant Projects, 2022 (Contd..1)
Myocardial Fibrosis - Discontinued Products, 2022